Skip to content
Study details
Enrolling now

Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms

Brigham and Women's Hospital
NCT IDNCT07136415ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

1,000

Study length

about 5 years

Ages

40–62

Sex

Female only

Locations

5 sites in MA, MI, NC +2

What this study is about

Researchers are testing whether digital therapy, trazodone, or daridorexant are more effective than each other at treating insomnia in women going through menopause. The trial will also look at the safety of these treatments. Participants will use one of three methods to treat their insomnia for 12 months and provide information about their sleep and health.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Participate in Cognitive behavioral therapy for insomnia (CBT-i)
  • 2.Take Daridorexant
  • 3.Take Trazodone

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

daridorexant, trazodone

Drug routes

oral (Oral Tablet)

Endpoints

Primary: PROMIS Sleep Disturbance T-score

Secondary: Insomnia Severity Index, Menopause-related Quality of Life, Occurrences of events of special interest and/or adverse events, PROMIS Anger Scale, PROMIS Anxiety Scale, PROMIS Cognitive Function Abilities Scale, PROMIS Depression Scale, PROMIS Fatigue Score

Procedures

therapy